{"id":16438,"date":"2025-02-14T17:46:00","date_gmt":"2025-02-14T17:46:00","guid":{"rendered":"https:\/\/megoconference.com\/?post_type=doctor&p=16438"},"modified":"2026-10-10T09:30:10","modified_gmt":"2026-10-10T09:30:10","slug":"dr-giuseppe-marchesani","status":"publish","type":"doctor","link":"https:\/\/megoconference.com\/ar\/doctor\/dr-giuseppe-marchesani\/","title":{"rendered":"Dr Giuseppe Marchesani, PhD"},"content":{"rendered":"\n
\n
\n
\n
\n \n
\n
\n
\n
\n
\n
MEGO \u2022 Conference Faculty<\/span>\n

Dr Giuseppe Marchesani, PhD<\/h1>\n

Clinical Biology Scientist | Specialist in Cell Biology & Immunology\n <\/p>\n

Book Your Seat Now \u2197<\/span><\/a>WhatsApp\n for Enquiry \u2197<\/span><\/a>CALL OUR TEAM \u2197<\/span><\/a><\/div>\n <\/div>\n
<\/div>\n <\/div>\n <\/section>\n \n
\n
\n
Dr Giuseppe Marchesani, PhD<\/span>\n

Profile<\/h2>\n <\/div>\n
\n

<\/p>\n

<\/p>\n

Dr Giuseppe Marchesani is a highly respected Clinical Biology Scientist with strong expertise in\n Cell Biology and Immunology. He is widely recognised for his contributions to regenerative\n medicine and advanced cell-based therapies. From the beginning of his career, Dr Giuseppe\n Marchesani focused on applying cell therapy to cardiovascular science.<\/p>\n

<\/p>\n

During this phase, his early work concentrated on producing clinical-grade cardiomyocytes derived\n from adipose-derived stem cells.<\/p>\n

<\/p>\n

Dr Marchesani believes innovation must always align with safety, ethics, and regulatory\n responsibility. In 2011, thereafter Dr Giuseppe Marchesani joined the Bioscience Institute in\n Italy. He was crucial to the development of pharma-grade manufacturing protocols for Mesenchymal Stem Cells<\/a>. His\n work significantly supported compliance with international quality and safety standards. These\n protocols helped advance the clinical use of stem cell-based therapies.<\/p>\n

<\/p>\n

<\/p>\n

<\/p>\n

Since 2014, Dr Marchesani has served as Director of Bioscience Clinic Middle East. In this role,\n he oversees advanced therapeutic protocol development in regenerative medicine. Dr Giuseppe\n Marchesani\u2019s recent research focuses on\u00a0MSC-derived exosome technologies<\/a>. He has\n worked extensively on optimising tangential flow filtration processes. He has also adjusted the\n presently used chromatography techniques for higher concentrations of exosomes.<\/p>\n

In 2022, as a milestone, his research led to the launch of a novel exosome-based product line. Dr\n Marchesani continues advancing pluripotent stem cell isolation and expansion techniques. These\n efforts support the future development of next-generation stem cell therapeutics. Since 2020, Dr\n Giuseppe Marchesani has served as Chief Technology Officer at Bioscience Group.<\/p>\n

<\/p>\n

He leads all innovation, strategy and work for the cell-based technology team. He completed his\n Executive MBA in 2023 to gain additional leadership skills. Through his work, Dr Giuseppe\n Marchesani is helping drive the advancement of regenerative medicine worldwide.<\/p>\n

<\/p>\n

\u00a0<\/h3>\n

<\/p>\n <\/div>\n <\/div>\n <\/section>\n \n

\n
\n
Dr Giuseppe Marchesani, PhD<\/span>\n

Qualifications<\/h2>\n <\/div>\n
\n